Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alembic Pharmaceuticals's Enterprise Value is ₹168,840 Mil.
Alembic Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Alembic Pharmaceuticals's EV-to-FCF for today is .
The historical rank and industry rank for Alembic Pharmaceuticals's EV-to-FCF or its related term are showing as below:
NSE:APLLTD'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 58.66
Current: 58.66
During the past 13 years, the highest EV-to-FCF of Alembic Pharmaceuticals was 58.66. The lowest was 0.00. And the median was 0.00.
NSE:APLLTD's EV-to-FCF is ranked worse than 78.35% of 568
companies
in the Drug Manufacturers industry
Industry Median: 21.015
vs NSE:APLLTD: 58.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alembic Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Alembic Pharmaceuticals's share price for today is ₹797.60.
Alembic Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹34.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alembic Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alembic Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alembic Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Alembic Pharmaceuticals's EV-to-FCF falls into.
Alembic Pharmaceuticals's current Enterprise Value is ₹168,840 Mil.
Alembic Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Alembic Pharmaceuticals (NSE:APLLTD) Overvalued in 2026?
Based on GuruFocus' analysis, Alembic Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹797.60 is trading 24.5% below its estimated GF Value™ of ₹1,055.95.
GuruFocus considers Alembic Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:APLLTD:
EV-to-FCF:
GF Value™: ₹1,055.95 vs. price of ₹797.60 (24.5% below fair value)
No single metric tells the full story. See the NSE:APLLTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
77GF Score
Get the complete analysis for NSE:APLLTD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:APLLTD has been successfully added to your 
